139 related articles for article (PubMed ID: 38629975)
1. Comparing PCSK9 Monoclonal Antibody Treatment Strategies Following Myocardial Infarction Using Negative Control Outcomes: A Target Trial Emulation Study.
Sloot R; Breskin A; Colantonio LD; Allmon AG; Yu Y; Sakhuja S; Chen L; Muntner P; Brookhart MA; Dhalwani N
Epidemiology; 2024 Jul; 35(4):579-588. PubMed ID: 38629975
[TBL] [Abstract][Full Text] [Related]
2. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Carter JL; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2020 Oct; 10(10):CD011748. PubMed ID: 33078867
[TBL] [Abstract][Full Text] [Related]
3. Race/ethnic and sex differences in the initiation of non-statin lipid-lowering medication following myocardial infarction.
Colvin CL; Poudel B; Bress AP; Derington CG; King JB; Wen Y; Chen L; Bittner V; Brown TM; Monda KL; Mues KE; Rosenson RS; Jackson EA; Muntner P; Colantonio LD
J Clin Lipidol; 2021; 15(5):665-673. PubMed ID: 34452823
[TBL] [Abstract][Full Text] [Related]
4. Persistence and Adherence to PCSK9 Inhibitor Monoclonal Antibodies Versus Ezetimibe in Real-World Settings.
Muntner P; Ghazi L; Jones J; Dhalwani N; Poudel B; Wen Y; Chen L; Wang Z; Bittner V; Kalich B; Farkouh ME; Woodward M; Colantonio LD; Rosenson RS
Adv Ther; 2024 Jun; 41(6):2399-2413. PubMed ID: 38691317
[TBL] [Abstract][Full Text] [Related]
5. Factors associated with time to initiation of a PCSK9 inhibitor after hospital discharge for acute myocardial infarction.
McKinley EC; Bittner VA; Brown TM; Chen L; Colantonio LD; Exter J; Orroth KK; Reading SR; Rosenson RS; Muntner P
J Clin Lipidol; 2022; 16(1):75-82. PubMed ID: 34848176
[TBL] [Abstract][Full Text] [Related]
6. PCSK9 monoclonal antibodies for the primary and secondary prevention of cardiovascular disease.
Schmidt AF; Pearce LS; Wilkins JT; Overington JP; Hingorani AD; Casas JP
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD011748. PubMed ID: 28453187
[TBL] [Abstract][Full Text] [Related]
7. In-hospital initiation of PCSK9 inhibitor and short-term lipid control in patients with acute myocardial infarction.
Lou B; Liu H; Luo Y; Jiang GT; Wu H; Wang C; Wu Y; Zhou B; Yuan Z; She J; Liu J
Lipids Health Dis; 2022 Oct; 21(1):105. PubMed ID: 36280861
[TBL] [Abstract][Full Text] [Related]
8. Effect of proprotein convertase subtilisin/kexin type 9 (PCSK9) monoclonal antibodies on new-onset diabetes mellitus and glucose metabolism: A systematic review and meta-analysis.
Cao YX; Liu HH; Dong QT; Li S; Li JJ
Diabetes Obes Metab; 2018 Jun; 20(6):1391-1398. PubMed ID: 29377473
[TBL] [Abstract][Full Text] [Related]
9. Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis.
Navarese EP; Kolodziejczak M; Schulze V; Gurbel PA; Tantry U; Lin Y; Brockmeyer M; Kandzari DE; Kubica JM; D'Agostino RB; Kubica J; Volpe M; Agewall S; Kereiakes DJ; Kelm M
Ann Intern Med; 2015 Jul; 163(1):40-51. PubMed ID: 25915661
[TBL] [Abstract][Full Text] [Related]
10. AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial.
Desai NR; Kohli P; Giugliano RP; O'Donoghue ML; Somaratne R; Zhou J; Hoffman EB; Huang F; Rogers WJ; Wasserman SM; Scott R; Sabatine MS
Circulation; 2013 Aug; 128(9):962-9. PubMed ID: 23884353
[TBL] [Abstract][Full Text] [Related]
11. AMG 145, a monoclonal antibody against PCSK9, facilitates achievement of national cholesterol education program-adult treatment panel III low-density lipoprotein cholesterol goals among high-risk patients: an analysis from the LAPLACE-TIMI 57 trial (LDL-C assessment with PCSK9 monoclonal antibody inhibition combined with statin thErapy-thrombolysis in myocardial infarction 57).
Desai NR; Giugliano RP; Zhou J; Kohli P; Somaratne R; Hoffman E; Liu T; Scott R; Wasserman SM; Sabatine MS
J Am Coll Cardiol; 2014 Feb; 63(5):430-3. PubMed ID: 24161333
[TBL] [Abstract][Full Text] [Related]
12. PCSK9 inhibitors and ezetimibe for the reduction of cardiovascular events: a clinical practice guideline with risk-stratified recommendations.
Hao Q; Aertgeerts B; Guyatt G; Bekkering GE; Vandvik PO; Khan SU; Rodondi N; Jackson R; Reny JL; Al Ansary L; Van Driel M; Assendelft WJJ; Agoritsas T; Spencer F; Siemieniuk RAC; Lytvyn L; Heen AF; Zhao Q; Riaz IB; Ramaekers D; Okwen PM; Zhu Y; Dawson A; Ovidiu MC; Vanbrabant W; Li S; Delvaux N
BMJ; 2022 May; 377():e069066. PubMed ID: 35508320
[TBL] [Abstract][Full Text] [Related]
13. Lipoprotein(a) Reduction With Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors: A Systematic Review and Meta-analysis.
Farmakis I; Doundoulakis I; Pagiantza A; Zafeiropoulos S; Antza C; Karvounis H; Giannakoulas G
J Cardiovasc Pharmacol; 2021 Mar; 77(3):397-407. PubMed ID: 33298738
[TBL] [Abstract][Full Text] [Related]
14. Optimal follow-up schedule for patients taking PCSK9 monoclonal antibodies in a health system: Analysis of specialty pharmacy clinical interventions.
Avlasevich V; Pilat S; Reindel K; Manou K; Trawinski A; Rightmier E
Am J Health Syst Pharm; 2024 Jun; 81(13):e358-e364. PubMed ID: 38347759
[TBL] [Abstract][Full Text] [Related]
15. Real-world study: Escalating targeted lipid-lowering treatment with PCSK9-inhibitors and lipoprotein apheresis.
Spitthöver R; Röseler T; Julius U; Heigl F; Schettler VJJ; Kühn R; Leebmann J; Raabe A; Knittel M; Schürfeld C; Moesenthin M; Bernhardt WM; Röseler E; Ketteler M; Heibges A; Klingel R
J Clin Apher; 2019 Aug; 34(4):423-433. PubMed ID: 30817043
[TBL] [Abstract][Full Text] [Related]
16. Meta-analysis of randomized clinical trials comparing PCSK9 monoclonal antibody versus ezetimibe/placebo in patients at high cardiovascular risk.
Ma W; Guo X; Ma Y; Hu Z
Atherosclerosis; 2021 Jun; 326():25-34. PubMed ID: 34004550
[TBL] [Abstract][Full Text] [Related]
17. Reduction of C-reactive protein, low-density lipoprotein cholesterol, and its relationship with cardiovascular events of different lipid-lowering therapies: A systematic review and meta-analysis of randomized controlled trials.
Yang W; Cai X; Lin C; Lv F; Zhu X; Han X; Ji L
Medicine (Baltimore); 2022 Sep; 101(37):e30563. PubMed ID: 36123891
[TBL] [Abstract][Full Text] [Related]
18. Low-Density Lipoprotein Cholesterol Lowering With Evolocumab and Outcomes in Patients With Peripheral Artery Disease: Insights From the FOURIER Trial (Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk).
Bonaca MP; Nault P; Giugliano RP; Keech AC; Pineda AL; Kanevsky E; Kuder J; Murphy SA; Jukema JW; Lewis BS; Tokgozoglu L; Somaratne R; Sever PS; Pedersen TR; Sabatine MS
Circulation; 2018 Jan; 137(4):338-350. PubMed ID: 29133605
[TBL] [Abstract][Full Text] [Related]
19. Meta-analysis of Randomized Controlled Trials Assessing the Impact of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies on Mortality and Cardiovascular Outcomes.
AlTurki A; Marafi M; Dawas A; Dube MP; Vieira L; Sherman MH; Gregoire J; Thanassoulis G; Tardif JC; Huynh T
Am J Cardiol; 2019 Dec; 124(12):1869-1875. PubMed ID: 31679643
[TBL] [Abstract][Full Text] [Related]
20. Clinical Benefit of Evolocumab by Severity and Extent of Coronary Artery Disease: Analysis From FOURIER.
Sabatine MS; De Ferrari GM; Giugliano RP; Huber K; Lewis BS; Ferreira J; Kuder JF; Murphy SA; Wiviott SD; Kurtz CE; Honarpour N; Keech AC; Sever PS; Pedersen TR
Circulation; 2018 Aug; 138(8):756-766. PubMed ID: 29626068
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]